Introduction
Myocardial perfusion scintigraphy in the UK: how much are we doing and how can we do more?
on behalf of the British Nuclear Cardiology Societya.kelion@rbh.nthames.nhs.uk
Keywords: myocardial perfusion scintigraphy; coronary artery disease
| The first 150 words of the full text of this article appear below. |
Myocardial perfusion scintigraphy (MPS) has been available as an investigation in known or suspected coronary artery disease for 30 years. In the USA, it is an established first line diagnostic and prognostic tool alongside the exercise ECG, and this is reflected in a high level of activity (35 000 studies per million population per year in 2002; Philips Medical Systems, personal communication). In Europe, and particularly in the UK, MPS has tended to be a second line investigation reserved for patients for whom coronary angiography is considered unattractive, and activity levels are correspondingly lower.1
In the UK, the National Institute for Health and Clinical Excellence (NICE) has published the results of its appraisal of MPS.2 As expected for an investigation with a large body of supporting literature, the findings were very positive. Referring to a submission from the professional bodies, NICE suggested that a UK activity level of 4000 studies
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
